Published on 4 May 2023 on Zacks via Yahoo Finance
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.25 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -8.70%. A quarter ago, it was expected that this molecular diagnostic company would post a loss of $0.25 per share when it actually produced a loss of $0.20, delivering a surprise of 20%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.